Concentric Reversible Visual Field Loss, Nyctalopia, and Dyschromatopsia with Ezetimibe Therapy

Concentric Reversible Visual Field Loss, Nyctalopia, and Dyschromatopsia with Ezetimibe Therapy

Blog Article

This is a case of ezetimibe-induced concentric field loss, dyschromatopsia, and nyctalopia in a patient with no prior history of retinal dystrophy or drug hypersensitivity.A 55-year-old Caucasian woman presents with a 1-year history of increasing concentric visual field loss, nyctalopia, photophobia, vista 5 vl5 and colour vision impairment.These symptoms correlated with the commencement of ezetimibe therapy 10 mg daily for hypercholesterolaemia.She demonstrated repeatable bilateral visual field constriction on 30-2 Humphrey visual filed testing and colour vision impairment on Ishihara plates (OD: s2720 1/17, OS: 1/17).Biochemical and radiological screening for carcinoma-associated retinopathy was unremarkable.

A working diagnosis of drug-induced rod-cone dysfunction was made.Her visual symptoms and field changes completely resolved 3 months after cessation of ezetimibe therapy.This case suggests that ezetimibe is a potential cause of rod-cone dysfunction and should be considered as a differential in patients with new unexplained visual symptoms.